title: Tyrosine kinase inhibitors in treatment of fibrous histiocytoma.
abstract: OBJECTIVE
  To describe potential beneficial effects of tyrosine kinase inhibitor in the treatment of unresectable/metastatic fibrous histiocytoma.
  
  
  METHODS
  We report a case of advanced stage fibrous histiocytoma with locally recurrent disease plus lung and bone metastatic deposits. Patient was treated with the tyrosine kinase inhibitor sunitinib.
  
  
  RESULTS
  Treatment with Sunitinib resulted in disease stabilization in the regional lesion and in good partial response for metastatic foci (reduction in number and size). After 13 months of treatment the patient is doing well with no tumor progression.
  
  
  CONCLUSIONS
  This case appears to be one of the first documentations of beneficial effect and potential long-term benefit of TKIs in the treatment of fibrous histiocytoma.
authors.affiliation: Panhellenic Association for Continual Medical Research (PACMeR), Section of Medical Oncology, Roditsa TK35100, Lamia, Greece. dvd.mauri@gmail.com
authors.forename: D
authors.initials: D
authors.lastname: Mauri
authors.forename: C
authors.initials: C
authors.lastname: Panou
authors.forename: A
authors.initials: A
authors.lastname: Valachis
authors.forename: K
authors.initials: K
authors.lastname: Kamposioras
authors.forename: L
authors.initials: L
authors.lastname: Tsali
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary*; D051677:Histiocytoma, Malignant Fibrous / Q000188:drug therapy / Q000473:pathology / Q000556:secondary*; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000473:pathology*; D008168:Lung / Q000187:drug effects / Q000473:pathology; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011758:Pyrroles / Q000627:therapeutic use*; D000077210:Sunitinib
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D047428:Protein Kinase Inhibitors; D011758:Pyrroles; D011505:Protein-Tyrosine Kinases; D000077210:Sunitinib